Qureight has raised almost £7 million in Series A funding to accelerate drug development in lung and heart disease. The Cambridge firm’s cloud platform leverages imaging data analytics and AI technology to help the best new drugs get approved. Its technology can be used by hospitals, clinical research organisations and multinational pharmaceutical companies to find … Continue reading Qureight backed with £7m to tackle lung & heart disease